Clinical Trials Logo

Lung Adenocarcinoma Metastatic clinical trials

View clinical trials related to Lung Adenocarcinoma Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT03345810 Completed - Clinical trials for Non Small Cell Lung Cancer

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

DURATION
Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable molecular alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based standard-combination chemotherapy but eligible for at-least mono-chemotherapy with gemcitabine or vinorelbine.

NCT ID: NCT03044626 Completed - Clinical trials for Nonsmall Cell Lung Cancer

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

FORCE
Start date: February 10, 2017
Phase: Phase 2
Study type: Interventional

AIO-YMO/TRK-0415 (FORCE) is a Phase 2, open-label of nivolumab, patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment for study group A and patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment for study Group B.

NCT ID: NCT02975752 Completed - Clinical trials for Lung Adenocarcinoma Metastatic

EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA

EGFRdelEx19
Start date: March 2015
Phase: N/A
Study type: Observational

First-line treatment with afatinib prolongs overall survival in patients with metastatic non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations. Conversely, somatic KRAS mutations are negative predictors for benefit from EGFR-targeting agents. In this study we want to compare a new highly sensitive method for the detection of EGFRdelEx19 and KRAS Exon 2 with targeted-resequencing multiplex-PCR (NGS).

NCT ID: NCT02946359 Recruiting - Clinical trials for Lung Adenocarcinoma Metastatic

A+C in Metastatic Lung Adenocarcinoma Cancer

Start date: July 2016
Phase: Phase 2
Study type: Interventional

This is a phase II, prospective, single arm, non comparative study with crizotinib combined with bevacizumab in treatment-naive lung adenocarcinoma cancer patients with ALK translocation or ROS1 translocation or MET amplification